Primary Outcomes:

Primary Outcome 1 - Measure: Number of subjects with adverse events (AE), including serious adverse events (SAEs).

Primary Outcome 1 - Time Frame: 3.5 years

Primary Outcome 2 - Measure: Determining dose limiting toxicities (DLT) and optimally tolerated dose range

Primary Outcome 2 - Time Frame: 3.5 years

Primary Outcome 3 - Measure: Evaluation of persistence of genetically modified T cells.

Primary Outcome 3 - Time Frame: 3.5 years

Primary Outcome 4 - Measure: Measurement of RCL in genetically modified T cells.

Primary Outcome 4 - Time Frame: 3.5 years

Condition:

• Urinary Bladder Cancer
• Melanoma
• Head and Neck Cancer
• Ovarian Cancer
• Non-Small Cell Lung Cancer
• Esophageal Cancer
• Gastric Cancer
• Synovial Sarcoma
• Myxoid Round Cell Liposarcoma

Eligibility

Criteria:
Inclusion Criteria:

1. Subject is ≥18 years of age at the time of signing the study informed consent.

2. Subject has histologically confirmed diagnosis of any one of the following cancers:
urothelial cancer (transitional cell cancer of the bladder, ureter, urethra or renal
pelvis), melanoma, squamous cell carcinoma of the head and neck, ovarian cancer, NSCLC
(squamous, adenosquamous, adenocarcinoma or large cell), esophageal (squamous and
adenocarcinoma) or gastric cancer, synovial sarcoma or MRCLS.

3. Subject is HLA-A*02 positive and subject's tumor shows expression of the MAGE-A4 RNA
or protein.

4. Subject has measurable disease according to RECIST v1.1 criteria prior to
lymphodepletion

5. Subject meets disease-specific requirements per protocol

6. Subject has anticipated life expectancy > 6 months prior to leukapheresis and >3
months prior to lymphodepletion.

Exclusion Criteria:

1. Subject is HLA-A*02:05 positive in either allele; Subject has HLA-A*02:07 as the sole
HLA-A*02 allele (e.g., a subject with HLA alleles A*02:04 and A*02:07 is eligible); or
Subject has any A*02 null allele (designated with an N", e.g., A*02:32N) as the sole
HLA-A*02 allele

2. Subject is receiving excluded therapy/treatment per protocol

3. Subject has symptomatic CNS metastases.

4. Subject has any other active malignancy besides the tumor under study within 3 years
prior to Screening. Subject has uncontrolled intercurrent illness.

5. Subject has active infection with HIV, HBV, HCV or HTLV

6. Subject is pregnant or breastfeeding.
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No